Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details)

v3.22.1
Stockholders Equity (Common Stock and Equity Offerings) (Narrative) (Details) - USD ($)
 3 Months Ended
Jan. 01, 2022
Jul. 22, 2016
Mar. 31, 2022
Mar. 31, 2021
Dec. 31, 2021
May 24, 2021
Dec. 04, 2020
Aug. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock, shares authorized     150,000,000   125,000,000      
Common stock par value (in dollars per share)     $ 0.0001   $ 0.0001      
Preferred stock, shares authorized     2,000,000   2,000,000      
Preferred stock, shares issued     250,000   250,000      
Aggregate value of shares subscribed     $ 27,000   $ 4,329,000      
Common stock, shares issued     100,287,838   93,582,991      
Common stock, shares issuable     27,393   2,536,607      
Shares available for future sale     587,542          
Fortress Biotech, Inc [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Issuance of common shares - Founders Agreement (in shares) 2,536,607   1,049,302          
Percentage of fully diluted equity 2.50% 2.50% 2.50%          
Expenses from related party transaction     $ 300,000 $ 100,000        
Issuance of common shares (in shares)     94,375 325,221        
Shares issued, price per share     $ 1.73 $ 4.16        
Common stock, shares issuable     27,393          
Proceeds from issuance of common shares     $ 2,800,000          
At the Market Offering [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Agent commission (as a percent)               3.00%
Issuance of common shares (in shares)     2,800,000 11,600,000        
Shares issued, price per share     $ 1.00 $ 4.17        
Proceeds from issuance of common shares     $ 2,800,000 $ 48,400,000        
Aggregate fees of stock issuance     49,000 900,000        
Registration Statements [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Sale of Stock aggregate offering price - Founders Agreement           $ 200,000,000.0 $ 100,000,000.0  
Shares available for future issuance - Founders Agreement     $ 11,700,000          
Class A Common Shares [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Common stock, shares issued     845,385   845,385      
General and administrative [Member] | Fortress Biotech, Inc [Member]                
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]                
Expenses from related party transaction     $ 800,000 $ 1,200,000